Pfizer’s Great Expectations: Sutent, Exubera Forecasts Exceed Those Of Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm projects 2010 annual sales of $2 bil. for the inhaled insulin and $1.5 bil. for the oncologic.
You may also be interested in...
Exubera Launch Falls Back To Early Autumn
Pfizer will roll out an education program for physicians and patients at the end of July and will launch the inhaled insulin in September.
Exubera Launch Falls Back To Early Autumn
Pfizer will roll out an education program for physicians and patients at the end of July and will launch the inhaled insulin in September.
Pfizer Breathes Easy: FDA Approves Exubera
Pfizer's Exubera is the first inhaled insulin to clear FDA; labeling recommends lung function testing.